Scientific article
Open access

Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link

Published inBiological Reviews, vol. 92, no. 3, p. 1755-1768
Publication date2017

Numerous molecular players in the process of tumour angiogenesis have been shown to offer potential for therapeutic targeting. Initially denoted to be involved in malignant transformation and tumour progression, the insulin-like growth factor (IGF) signalling axis has been subject to therapeutic interference, albeit with limited clinical success. More recently, IGFs and their receptors have received attention for their contribution to tumour angiogenesis, which offers novel therapeutic opportunities. Here we review the contribution of this signalling axis to tumour angiogenesis, the mechanisms of resistance to therapy and the interplay with other pro-angiogenic pathways, to offer insight in the renewed interest in the application of IGF axis targeting agents in anti-cancer combination therapies.

  • Drug Delivery Systems
  • Humans
  • Neoplasms/physiopathology/therapy
  • Neovascularization, Pathologic
  • Protein Binding
  • Signal Transduction
  • Somatomedins/antagonists & inhibitors/metabolism
Citation (ISO format)
VAN BEIJNUM, Judy R et al. Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link. In: Biological Reviews, 2017, vol. 92, n° 3, p. 1755–1768. doi: 10.1111/brv.12306
Main files (1)
Article (Published version)
ISSN of the journal0006-3231

Technical informations

Creation06/25/2020 4:24:00 PM
First validation06/25/2020 4:24:00 PM
Update time03/15/2023 10:12:41 PM
Status update03/15/2023 10:12:40 PM
Last indexation02/12/2024 11:52:29 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack